Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia

  title={Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia},
  author={Kazunari Yoshida and Hiroyoshi Takeuchi},
  journal={Behavioural Brain Research},

Comorbidities and the right dose: antipsychotics

The pharmacokinetic profiles of seven oral antipsychotics are reviewed, focusing on renal and hepatic impairment, and factors liable to impact antipsychotic dosage are numerous and their subsequent effects often hard to predict, due to multi-level interactions and compensatory phenomena.

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics

Two cases of exercise-associated worsening of extrapyramidal symptoms in two individuals with schizoaffective disorder treated with a long-acting injectable antipsychotic medication over the course of a 12-week exercise program are reported.

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies

Akathisia, the most common cariprazine-related AE, was mild/moderate and resulted in few study discontinuations; symptoms were well managed and most patients remained on treatment.

Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: a Randomized Controlled Trial.

FEDN patients with schizophrenia with SCZ were effectively treated for their psychotic and depressive symptoms while experiencing significantly fewer adverse effects using half the usual ziprasidone dose when combined with sertraline.

A Study to Assess the Effectiveness of Psychoeducation on Knowledge of Antipsychotics Drugs among Caregivers of Schizophrenia Patients at Gauhati Medical College and Hospital, Guwahati, Assam

The result showed that Psychoeducation of antipsychotic drug was highly effective and consistent with the literature and have support from the other studies.

Efficacy and Safety of Low-Dose Brexpiprazole for Acute Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials

The results indicated that low-dose brexpiprazole may be not superior for improving the efficacy and safety for acute schizophrenia compared to placebo and standard- dose brexpIPrazole, and may cause additional risk of increasing body weight.

Challenging the Minimum Effective Antipsychotic Dose During Maintenance: Implications From 10-Year Follow-Up of First Episode Psychosis

A substantial proportion of patients could achieve good functioning under low-dose antipsychotic maintenance after first-episode psychosis, even if they could not completely withdraw antipsychotics in the long term.

Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-analysis

Compared with the placebo group, the APM group was significantly superior in relation to score reduction on the depression severity scales and CGI-S and inferior in comparison to 8 of 23 individual adverse events.

Olanzapine Reduction From High Dose to Standard Dose

The findings suggest that high-dose olanzapine can be reduced to the standard dose after stabilization of symptoms in most patients with schizophrenia.



Adverse Effects of Atypical Antipsychotics

It is concluded that broad statements comparing the relative risk of specific adverse effects between ‘atypical’ and ‘conventional’ antipsychotics are largely meaningless; rather, comparisons should be made between specific atypical and specific conventional drugs.

Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis.

Clinicians can dose an antipsychotic at 2-fold or 3-fold MED for patients with acute schizophrenia but should closely monitor side effects, according to a meta-analysis.

Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.

In chronic schizophrenia patients with acute exacerbations, doses higher than the identified 95% effective doses may on average not provide more efficacy and some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau.

Dose Reduction/Discontinuation of Antipsychotic Drugs in Psychosis; Effect on Cognition and Functional Outcomes

These measures of functional outcome should be considered in deciding which strategy of antipsychotic treatments is beneficial in individual cases with FEP or schizophrenia.

Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia

  • V. O’Keane
  • Medicine, Psychology
    Journal of psychopharmacology
  • 2008
Preliminary findings from the studies suggest that active management of bone loss in those with antipsychotic-associated bone disease may halt or even reverse this process.

Incident users of antipsychotic agents and future use of cholesterol-lowering drugs: an observational, pharmacoepidemiologic study.

The results may support the notion that patients treated with antipsychotic agents receive suboptimal care with regard to metabolic adverse effects, based on the recognized negative impact of antipsychotics on serum lipids.

Management of common adverse effects of antipsychotic medications

  • T. StroupNeil Gray
  • Psychology, Medicine
    World psychiatry : official journal of the World Psychiatric Association
  • 2018
This paper reviews management strategies for the most frequent side effects and identifies common principles intended to optimize net antipsychotic benefits, which include only use antipsychotics if the indication is clear; only continue antipsychosis if a benefit is discernible.